US BARDA awards Elusys $68.9 million to pursue anthrax antitoxin
This article was originally published in Scrip
Executive Summary
Elusys Therapeutics snagged a five-year $68.9 million contract from the US Biomedical Advanced Research and Development Authority (BARDA) to advance the firm's intramuscular antitoxin Anthim (ETI-204) to prevent disease and death from exposure to anthrax.